entertainment -WSS

entertainment

author：leisure time 2025-09-28 21:57:37 - browse：5

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Problems with a popular proposal to regulate AI in health care

WSS

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Adopting new red light myopia treatments may be short

AI gets buy

Late stage cancers on the rise after pandemic delayed screenings

The a glaring gap in research on serious mental illness and primary care

Adopting new red light myopia treatments may be short

explore

entertainment

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

2 officers injured in shooting in Orlando, police say

Novavax promises a turnaround & Lilly roils the obesity market

Bernie brings in new pharma CEOs to talk drug prices

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Group behind ProMed defends move to subscription

Dobbs anniversary: the lost opportunity of abortion as health care

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Drug repurposing or repositioning? The language matters

Devoted Health’s losses in Medicare Advantage persist

leisure time

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Adopting new red light myopia treatments may be short

Surgery pushed Ben Carson to fame

Problems with a popular proposal to regulate AI in health care

2 officers injured in shooting in Orlando, police say

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

explore

leisure time

explore

hotspot